Using utilities

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 223-225

  Uhlig, Till ^a   Garratt, Andrew ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; EDITORIAL; EURO QUALITY OF LIFE 5D QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH SERVICE; HEALTH STATUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RHEUMATOLOGY; SHORT FORM 36; VISUAL ANALOG SCALE;

HEALTH STATUS; HEALTH SURVEYS; HUMANS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 76649108196     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091397     Document Type: Editorial

References (17)

1. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
2. Meenan RF, Mason JH, Anderson JJ, Guccione AA, Kazis LE. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales health status questionnaire. Arthritis Rheum 1992;35:1-10.
3. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
4. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
5. Garratt A. Patient reported outcome measures in trials. BMJ 2009;338:a2597.
6. Linde L, Sørensen J, Østergaard M, Hørslev-Petersen K, Hetland ML. Does clinical remission lead to normalization of EQ-5D in patients with RA and is the selection of remission criteria important? J Rheumatol 2010:37:285-90.
7. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003;1:54.
8. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;324:1417.
9. Boonen A, Maetzel A, Drummond M, Suarez-Almazor M, Harrison M, Welch V, et al. The OMERACT initiative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol 2009;36:2045-9.
10. Bansback N, Marra C, Tsuchiya A, Anis A, Guh D, Hammond T, et al. Using the Health Assessment Questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum 2007;57:963-71.
11. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
12. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663-75.
13. Uhlig T, Loge JH, Kristiansen IS, Kvien TK. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 2007;34:1241-7.
14. Kind P, Macran S. A five-level version of the EQ-5D. Value Health 2004;7:637-56.
15. Pickard AS, De Leon MC, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care 2007;45:259-63.
16. Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level system with a five-level version. Value Health 2008;11:275-84.
17. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 2002;47:655-61.